NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
West German Study Group
International Extranodal Lymphoma Study Group (IELSG)
Merck KGaA, Darmstadt, Germany
University Hospital, Clermont-Ferrand